market access

News

NICE recommends regular NHS funding for Roche's lymphoma dru...

NICE has recommended regular NHS funding for Roche’s Polivy in certain lymphoma patients in final draft guidance, overturning a previous rejection.

News

Roche takes on pricey rivals as FDA approves SMA drug

Roche is hoping to undercut hugely expensive rivals after the FDA approved its oral spinal muscular atrophy (SMA) drug Evrysdi (risdiplam).

News

NICE backs kidney cancer combination from Merck KGaA and Pfi...

NICE has said a combination of Merck KGaA’s Bavencio and Pfizer’s Inlyta should be available as a first line option for kidney cancer patients for NHS patients in England.

News

NICE backs NHS use for Astellas' Xospata after rethink

NICE has recommended regular NHS funding for Astellas’ Xospata (gilteritinib) monotherapy for certain adult patients with acute myeloid leukaemia

Partner Content

Windrose Consulting Group Managing Parners

Partner Content

Windrose Consulting Group acquires Parioforma

Windrose acquires Parioforma as part of growth strategy

News

All EU Flags in front of the European Parliament, Flags in front of the European Parliament, Strasbourg, Alsace, France

Survey shows patients wait six times longer than EU neighbou...

Patients in some European countries are waiting up to six times longer for access to medicines than their neighbours, according to a survey by Europe’s pharma trade body.

NICE recommends regular NHS funding for Roche's lymphoma dru...

Roche takes on pricey rivals as FDA approves SMA drug

NICE backs kidney cancer combination from Merck KGaA and Pfi...

NICE backs NHS use for Astellas' Xospata after rethink

Windrose Consulting Group acquires Parioforma

Survey shows patients wait six times longer than EU neighbou...

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

market access

Editor's Picks